Figure. Reasons for TMP/SMX avoidance and TMP/SMX rechallenge outcomes among immunocompromised patients in whom TMP/SMX prophylaxis for Pneumocystis jirovecii pneumonia prophylaxis was avoided, Stanford, California, USA. *Failed TMP/SMX introduction because of rash or GI symptoms that were not severe. †Developed intractable nausea and vomiting after TMP/SMX was introduced and did not tolerate rechallenge. GI, gastrointestinal; TMP/SMX, trimethoprim/sulfamethoxazole.